A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...
The quadrivalent HPV vaccine, developed by multinational pharmaceutical company Merck, was approved on Jan 8 for males on the Chinese mainland. The vaccine targets HPV types 6, 11, 16 and 18. The ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...
Non-persistent human papillomavirus (HPV) infections are characterized by a sharp increase in viral load followed by a long plateau, according to a study published January 21st in the open-access ...
Non-persistent human papillomavirus (HPV) infections are characterized by a sharp increase in viral load followed by a long ...
HPV can cause a variety of cancers, including cervical. New mortality data for women under 25 point to the success of the HPV vaccine.
The human papillomavirus (HPV) is the most common sexually transmitted infection, and most people will have exposure at some ...
Non-persistent human papillomavirus (HPV) infections are characterized by a sharp increase in viral load followed by a long plateau, according to a study published January 21st in the open-access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback